Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 10/25/23
End: 06/30/26
Due: 06/30/27
Phase: N/A
Priority: Normal
Start: 06/08/21
End: 06/20/22
Due: 06/20/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease | NCT06114329 | AceLink Therapeutics, Inc. | user2@example.com | None | 2023-10-25 | 2026-06-30 | 2027-06-30 | - | - | 2025-07-14 |
| To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers | NCT04908462 | AceLink Therapeutics, Inc. | user2@example.com | None | 2021-06-08 | 2022-06-20 | 2023-06-20 | - | - | 2025-07-14 |